SAN ANTONIO: A court has ruled that drug manufacturer Actavis PLC’s attempted switch of patented Alzheimer’s medication, which halted distribution of the old drug before its patent expires this summer, violates antitrust law.
The decision unsealed this week explains the ruling last week by a three-judge panel of the 2nd U.S. Circuit Court of Appeals that requires the Irish company to keep distributing Namenda until 30 days after its patent expires on July 11…